

1. A pharmaceutical composition comprising about 1.54 mg/ml nivolumab, about 4.62 mg/ml ipilimumab, about 18.46 mM Tris hydrochloride (HCl), about 1.54 mM sodium citrate dihydrate, about 1.15% mannitol, about 96.15 mM NaCl, about 93.85 μ M pentetic acid, and about 0.012 % PS80.
2. The composition of claim 1, wherein the composition
 - (i) is stable at about 5°C for at least about 1 week;

- (ii) is stable at about 40°C for at least about 1 week; or
- (iii) is stable at about 25°C for at least about 1 week.

3. A kit comprising the composition of claim 1 and instructions to administer the composition to a subject in need thereof.

4. The pharmaceutical composition of claim 1, wherein the pH of the composition is about 6.0, about 6.2, about 6.5, about 6.6, or about 7.0.
5. The pharmaceutical composition of claim 1, wherein the pH is about 6.2.
6. The pharmaceutical composition of claim 1, wherein the pH is 6.2.
7. The pharmaceutical composition of claim 1, wherein the pH is 6.1.
8. The pharmaceutical composition of claim 1, comprising 1.54 mg/mL nivolumab and 4.62 mg/ml ipilimumab.
9. The pharmaceutical composition of claim 1, comprising about 30 mg nivolumab and about 90 mg ipilimumab.
10. The pharmaceutical composition of claim 1, comprising about 40 mg nivolumab and about 120 mg ipilimumab.
11. The pharmaceutical composition of claim 1, comprising 18.46 mM Tris hydrochloride (HCl).
12. The pharmaceutical composition of claim 1, comprising 1.54 mM sodium citrate dihydrate.
13. The pharmaceutical composition of claim 1, comprising 1.15% mannitol.
14. The pharmaceutical composition of claim 1, comprising 96.15 mM NaCl.
15. The pharmaceutical composition of claim 1, comprising 93.85 μ M pentetic acid.
16. The pharmaceutical composition of claim 1, comprising 0.012% PS80.
17. The pharmaceutical composition of claim 1, comprising 18.46 mM Tris hydrochloride (HCl) and 1.54 mM sodium citrate dihydrate.
18. The pharmaceutical composition of claim 1, comprising 1.15% mannitol, 96.15 mM NaCl, and 93.85 μ M pentetic acid.

19. The pharmaceutical composition of claim 1, comprising 18.46 mM Tris hydrochloride (HCl), 1.54 mM sodium citrate dihydrate, 1.15% mannitol, 96.15 mM NaCl, and 93.85 μ M pentetic acid.
20. The pharmaceutical composition of claim 1, comprising 18.46 mM Tris hydrochloride (HCl), 1.54 mM sodium citrate dihydrate, 1.15% mannitol, 96.15 mM NaCl, 93.85 μ M pentetic acid, and 0.012% PS80.
21. The pharmaceutical composition of claim 20, wherein the pH is 6.2 at 25 °C.
22. The pharmaceutical composition of claim 1, wherein the pH is between about 6.0 and about 7.0.
23. The pharmaceutical composition of claim 1, wherein the composition:
- (i) is stable at 5°C for at least 1 week;
 - (ii) is stable at 40°C for at least 1 week; or
 - (iii) is stable at 25°C for at least 1 week.
24. A pharmaceutical composition comprising 1.54 mg/ml nivolumab, 4.62 mg/ml ipilimumab, 18.46 mM Tris hydrochloride (HCl), 1.54 mM sodium citrate dihydrate, 1.15% mannitol, 96.15 mM NaCl, 93.85 μ M pentetic acid, and 0.012% PS80.
25. The pharmaceutical composition of claim 24, wherein the pH is between about 6.0 and about 7.0.
26. The pharmaceutical composition of claim 24, wherein the pH is 6.2 at 25 °C.
27. The pharmaceutical composition of claim 24, wherein the composition:
- (i) is stable at 5°C for at least 1 week;
 - (ii) is stable at 40°C for at least 1 week; or
 - (iii) is stable at 25°C for at least 1 week.

28. The pharmaceutical composition of claim 24, comprising about 30 mg nivolumab and about 90 mg ipilimumab.
29. The pharmaceutical composition of claim 24, comprising about 40 mg nivolumab and about 120 mg ipilimumab.